Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(0.94)
# 1963
Out of 5,326 analysts
162
Total ratings
38.74%
Success rate
3.08%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
AARD Aardvark Therapeutic... | Reiterates: Overweight | 50 50 | 8.27 | 504.59% | 2 | Apr 1, 2025 | |
ARTV Artiva Biotherapeuti... | Maintains: Overweight | 23 20 | 2.44 | 719.67% | 2 | Mar 25, 2025 | |
BBIO BridgeBio Pharma | Reiterates: Overweight | 95 95 | 35.97 | 164.11% | 10 | Feb 21, 2025 | |
KRYS Krystal Biotech | Reiterates: Overweight | 215 | 169.31 | 26.99% | 5 | Feb 20, 2025 | |
ASND Ascendis Pharma | Maintains: Outperform | 220 260 | 160.38 | 62.11% | 2 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 50 50 | 6.46 | 673.99% | 2 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 5 5 | 0.73 | 584.93% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 200 200 | 32.05 | 524.02% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 25 25 | 17.41 | 43.6% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 65 65 | 7.42 | 776.01% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 16 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 30 30 | 14.63 | 105.06% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 90 90 | 33.38 | 169.62% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | n/a | n/a | n/a | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 15 15 | 0.3 | 4900% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 54 53 | 30.93 | 71.35% | 5 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 65 65 | 38.23 | 70.02% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 50 60 | 40.49 | 48.18% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 50 50 | 1.27 | 3837.01% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 75 75 | 21.45 | 249.65% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 43 5 | 1.26 | 296.83% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 40 | n/a | n/a | 1 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 20 11 | 1.39 | 691.37% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 24 15 | n/a | n/a | 3 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 2 2 | n/a | n/a | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 140 130 | 105.82 | 22.85% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | 760 | 599.33 | 26.81% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 15 | 12.55 | 19.52% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 50 | n/a | n/a | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 350 | n/a | n/a | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 45 | n/a | n/a | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 55 | 8.16 | 574.02% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 30 | 1.64 | 1729.27% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 480 | n/a | n/a | 1 | Sep 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 15 | n/a | n/a | 3 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: In-Line | n/a | n/a | n/a | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 2 | Apr 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 222 250 | 320.9 | -22.09% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 196 0 | n/a | n/a | 2 | Sep 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 3500 4600 | 4.17 | 110211.75% | 4 | Jun 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 2 | Jun 11, 2018 |